DE602006015050D1 - Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür - Google Patents

Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Info

Publication number
DE602006015050D1
DE602006015050D1 DE602006015050T DE602006015050T DE602006015050D1 DE 602006015050 D1 DE602006015050 D1 DE 602006015050D1 DE 602006015050 T DE602006015050 T DE 602006015050T DE 602006015050 T DE602006015050 T DE 602006015050T DE 602006015050 D1 DE602006015050 D1 DE 602006015050D1
Authority
DE
Germany
Prior art keywords
hybrid molecules
tat
hiv
polypeptides
hiv hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015050T
Other languages
English (en)
Inventor
Susan Barnett
Rino Rappuoli
Victoria Sharma
Indresh Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE602006015050D1 publication Critical patent/DE602006015050D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006015050T 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür Active DE602006015050D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65063505P 2005-02-03 2005-02-03
PCT/US2006/003935 WO2006084179A2 (en) 2005-02-03 2006-02-03 Hiv tat-cd4 hybried molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602006015050D1 true DE602006015050D1 (de) 2010-08-05

Family

ID=36777987

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015050T Active DE602006015050D1 (de) 2005-02-03 2006-02-03 Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Country Status (8)

Country Link
US (2) US8168194B2 (de)
EP (1) EP1893650B1 (de)
CN (1) CN101146827A (de)
AT (1) ATE471947T1 (de)
CA (1) CA2597040A1 (de)
DE (1) DE602006015050D1 (de)
WO (1) WO2006084179A2 (de)
ZA (1) ZA200707138B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569562C (en) 2004-06-08 2013-12-03 Vega Masignani Fusion proteins comprising cd4 minimal modules and methods of use thereof
EP1893650B1 (de) 2005-02-03 2010-06-23 Novartis Vaccines and Diagnostics, Inc. Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
AU2008223469B2 (en) * 2007-03-02 2013-09-05 Nono Inc. Treating stroke and other diseases without inhibiting N-type calcium channels
EP2706356A1 (de) * 2012-09-06 2014-03-12 Laboratorios Del. Dr. Esteve, S.A. Verfahren zur Identifizierung HIV-neutralisierender Antikörper
CN111303243B (zh) * 2020-02-25 2021-07-27 徐州医科大学 治疗缺血性脑损伤的小肽tat-akpd及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5817767A (en) 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
ATE207760T1 (de) 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
FR2799974B1 (fr) 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
AU2002316578A1 (en) 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
CA2482744C (en) 2002-05-07 2013-11-26 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
GB0218817D0 (en) 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
CA2569562C (en) * 2004-06-08 2013-12-03 Vega Masignani Fusion proteins comprising cd4 minimal modules and methods of use thereof
EP1893650B1 (de) 2005-02-03 2010-06-23 Novartis Vaccines and Diagnostics, Inc. Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür

Also Published As

Publication number Publication date
EP1893650B1 (de) 2010-06-23
WO2006084179A3 (en) 2006-12-14
US20080317779A1 (en) 2008-12-25
CN101146827A (zh) 2008-03-19
ZA200707138B (en) 2008-11-26
EP1893650A2 (de) 2008-03-05
CA2597040A1 (en) 2006-08-10
US8168194B2 (en) 2012-05-01
US8637044B2 (en) 2014-01-28
US20120183557A1 (en) 2012-07-19
ATE471947T1 (de) 2010-07-15
WO2006084179A2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
TW200738711A (en) Chemical compounds
NO20082531L (no) Neuropilinantagonister
WO2007027999A3 (en) Chemical compounds
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
ATE506112T1 (de) Adsorption und freigabe von stickstoffmonoxid in metallorganischen gerüsten
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
BR112012000167A2 (pt) Catalisadores de hidrossililação
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
EA200870265A1 (ru) Функционально активные антитела
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
WO2014153056A8 (en) Cancer treatment using antibodies that bind cell surface grp78
ATE507242T1 (de) Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
EP1983002A3 (de) Tyrosinphosphorylations-Stellen und spezifische Antikörper
DE602006015050D1 (de) Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
TR201909522T4 (tr) Anti-tümör aktivitesine sahip bir nonapeptit.
SG153796A1 (en) Fusion proteins comprising cd4 minimal modules and methods of use thereof
MY155340A (en) Use of cathepsin c
EP1983003A3 (de) Tyrosinphosphorylationsstellen und spezifische Antikörper
ATE535552T1 (de) Phenantrolinhaltige komplexe
MX2008008768A (es) Tratamiento contra el vih.
WO2009099601A3 (en) Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3
EP1988103A3 (de) Tyrosinphosphorylationsstellen und spezifische Antikörper
NO20084599L (no) Sammensetninger, fremgangsmater og kit ved anvendelse av adenosin og inosin i kombinasjon for diagnose og behandling
GB0818080D0 (en) Immunogenic peptides